SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

50 Progress Made Under New Ownership Inherited Challenges ▪ August / September U.S. net sales represented the best two months of 2018 ▪ Optimized cost structure driving improved profitability; positive EBITDA observed in August ▪ Significant improvements in net sales per TRx in the U.S. ▪ Multiple ongoing BD discussions focused on monetizing OUS territories ▪ Disruption from bankruptcy process ▪ Significantly bloated infrastructure and costs ▪ Orexigen’s lack of focus on key PBMs, resulting in certain 2019 exclusions ▪ Product recall initiated in August ▪ Declining revenue per TRx in the U.S. ▪ The acquisition of Contrave ® through Nalpropion demonstrates the success of deploying Pernix ’ s platform and management team to drive efficiencies and improved profitability Nalpropion / Contrave ® Momentum